Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.

[1]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[2]  J. Witjes,et al.  Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non‐muscle‐invasive bladder cancer treated with intravesical chemotherapy , 2014, BJU international.

[3]  Richard Sylvester,et al.  Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. , 2013, European urology.

[4]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[5]  M. Babjuk,et al.  Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. , 2013, European urology.

[6]  D. Lamm,et al.  Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS) , 2013, BJU international.

[7]  Y. Lotan,et al.  Reported use of intravesical therapy for non‐muscle‐invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey , 2012, BJU international.

[8]  Y. Lotan,et al.  Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. , 2012, European urology.

[9]  M. Litwin,et al.  Compliance with guidelines for patients with bladder cancer , 2011, Cancer.

[10]  K. Chamie,et al.  Compliance with guidelines for patients with bladder cancer: variation in the delivery of care , 2011 .

[11]  V. Hernández,et al.  External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer , 2011, World Journal of Urology.

[12]  G. Morgia,et al.  Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblastic Therapy Italian Study , 2010, Urologia Internationalis.

[13]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[14]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[15]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[16]  A. Böhle,et al.  Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2004, Urology.

[17]  Richard Sylvester,et al.  Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .

[18]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[19]  Andreas Böhle,et al.  Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) , 2014 .

[20]  J. Witjes,et al.  [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. , 2012, Actas urologicas espanolas.